

 Early Warning System

IFC-45021

Fosun Pharma GHP



Quick Facts

| | |
|--------------------------------|---|
| Countries | China |
| Financial Institutions | International Finance Corporation (IFC) |
| Status | Proposed |
| Bank Risk Rating | B |
| Borrower | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
| Sectors | Industry and Trade |
| Investment Type(s) | Loan |
| Investment Amount (USD) | \$ 200.00 million |
| Loan Amount (USD) | \$ 200.00 million |
| Project Cost (USD) | \$ 420.00 million |



Project Description

According to the bank document, "The proposed IFC investment will primarily support Fosun Pharma's manufacturing and distribution of COVID-19 related medical products, including the COVID-19 vaccine co-developed by Pfizer / BioNTech and COVID-19 testing kits and in China (the "Project").

Fosun Pharma is headquartered in Shanghai, China. The Project involves capital expenditures associated with the expansion of cold-chain warehousing and distribution networks across China. "



Investment Description

- International Finance Corporation (IFC)

"The Project cost is estimated to be up to US\$420 million. IFC's proposed investment is a straight senior loan of up to US\$200 million with a tenor of up to seven years".



Private Actors Description

Shanghai Fosun Pharmaceutical (Group) Co. Ltd., (“Fosun Pharma”, or the “Company”) is a manufacturer of pharmaceutical products and medical devices in China. Fosun Pharma has been listed on the Shanghai Stock Exchange since 1998 and Hong Kong Stock Exchange since 2012. The Sponsor is Fosun International Limited (“Fosun International”), which owns 36.6% of the Company while 63.4% is held by public shareholders.



| Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
|-----------------|----------------------|------------------------|----------|--|----------------------|------------------------|
| - | - | - | - | Fosun International Limited | Parent Company | - |
| - | - | - | - | Shanghai Fosun Pharmaceutical (Group) Co. Ltd. | Undisclosed | - |



Contact Information

1/ The Project Contact

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Contact: Mr. Zhang Xiang

Title: Finance Manager

Phone number: +86-21-33987000

Email: zhangxiang1@fosunpharma.com

Address: Building A, No. 1289 Yishan Road, Shanghai, China

Website: <https://www.fosunpharma.com/en/>

2/ The IFC Contact

General IFC Inquiries

IFC Communications

2121 Pennsylvania Avenue, NW

Washington DC 20433

Telephone: 202-473-3800

Fax: 202-974-4384

3/ Local Access for Project Documentation

Environmental documents will be made accessible to locally affected communities.

ACCESS TO INFORMATION

You can submit a request for information disclosure at: <https://disclosures.ifc.org/#/inquiries>

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at <http://www.cao-ombudsman.org>